News and Announcements
Alcidion to Present at WA Broker Meets Biotech
- Published September 09, 2016 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
8th September 2016, ASX Announcement
Alcidion Group Limited (ASX:ALC) today announced that it will present at the AusBioTech WA Broker Meets Biotech Lunch on Thursday, 15 September 2016.
Executive Director, Mr. Nathan Buzza will present to brokers, investors and financial advisors, on behalf of Alcidion. Updating the group on the latest developments within the company, since being publicly listed in February 2016.
This event will be hosted by Mr. Brian Leedman, Co-Chairman of AusBiotech WA and Non-Executive Director to Alcidion GroupLimited.
It will feature a keynote presentation form Mr. Mark Dehring, Head of Investor Relations for CSL Limited, an overview of the biotechnology industry investment landscape from Mr. Stuart Roberts, Life Sciences Analyst at NDF Research.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
